# Viatris Inc. (VTRS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $15.77 (-2.65%)

> Viatris Inc. is a global healthcare company that delivers quality medicines and innovative solutions to improve health access worldwide. It offers a dynamic portfolio spanning generics, including commoditized, complex products and biosimilars, alongside globally recognized established brands such as Lipitor, Norvasc, Lyrica, and Viagra, and an expanding range of innovative medicines. The company operates across more than 10 major therapeutic areas, with key focus on dermatology, ophthalmology, and gastroenterology. Viatris leverages best-in-class manufacturing, scientific expertise, and commercial capabilities through 26 manufacturing and packaging sites worldwide, over 1,400 approved molecules, and global centers in Pittsburgh, Pennsylvania; Shanghai, China; and Hyderabad, India. Headquartered in the United States and incorporated in Delaware, Viatris serves patients in over 165 countries, bridging the divide between generics and brands to address diverse healthcare needs comprehensively.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $14.25B | $5.01B | -$2.66B | — | — |
| 2024 | $14.69B | $5.62B | $10M | — | — |
| 2023 | $15.39B | $6.44B | $766M | — | — |
| 2022 | $16.22B | $6.50B | $1.61B | — | — |
| 2021 | $17.81B | $5.58B | -$34M | — | — |
| 2020 | $11.82B | $3.80B | -$211M | — | — |
| 2019 | $11.37B | $3.90B | $716M | — | — |
| 2018 | $11.27B | $4.00B | $906M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $37.19B | $22.48B | $14.71B | $1.32B | $12.48B |
| 2024 | $41.50B | $22.87B | $18.64B | $735M | $14.04B |
| 2023 | $47.69B | $27.22B | $20.47B | $992M | $16.19B |
| 2022 | $50.02B | $28.95B | $21.07B | $1.26B | $18.02B |
| 2021 | $54.84B | $34.35B | $20.49B | $701M | $19.72B |
| 2020 | $61.55B | $38.60B | $22.95B | $844M | $22.43B |
| 2019 | $31.26B | $19.37B | — | $476M | $11.21B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $2.32B | $379M | $1.94B |
| 2024 | $2.30B | $326M | $1.98B |
| 2023 | $2.90B | $377M | $2.52B |
| 2022 | $3.00B | $406M | $2.59B |
| 2021 | $3.02B | $457M | $2.56B |
| 2020 | $1.23B | $243M | $989M |
| 2019 | $1.80B | $213M | $1.59B |
| 2018 | $2.34B | $252M | $2.09B |

Source: [CompaniesByCap](https://companiesbycap.com/company/VTRS)